Evidence map›Paper›PMID 35520102›Full record

ArticleIEEE transactions on radiation and plasma medical sciences2022

Learning-based Cancer Treatment Outcome Prognosis using Multimodal Biomarkers.

Maliazurina Saad, Shenghua He, Wade Thorstad, Hiram Gay, Daniel Barnett, Yujie Zhao, Su Ruan, Xiaowei Wang, Hua Li

Abstract read
In one paragraph

Article in IEEE transactions on radiation and plasma medical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Maliazurina SaadDepartment of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, IL, USA. She is now with the MD Anderson Cancer Center, Houston, TX, USA.
Shenghua HeDepartment of Computer Science and Engineering, Washington University, Saint louis, MO, USA.
Wade ThorstadDepartment of Radiation Oncology, Washington University School of Medicine, Saint louis, MO, USA.
Hiram GayDepartment of Radiation Oncology, Washington University School of Medicine, Saint louis, MO, USA.
Daniel BarnettCarle Cancer Center, Carle Foundation Hospital, Urbana, IL, USA.
Yujie ZhaoMao Clinic at Florida, Jacksonville, FL, USA.
Su RuanLaboratoire LITIS (EA 4108), Equipe Quantif, University of Rouen, France.
Xiaowei WangDepartment of Pharmacology and Bioengineering, University of Illinois at Chicago, Chicago, IL, USA.
Hua LiDepartment of Bioengineering, University of Illinois at Urbana-Champaign, Cancer Center at Illinois, and Carle Foundation Hospital, Urbana, IL, USA.

Funding

MICRORNA BIOMARKERS FOR OROPHARYNGEAL CANCERR01DE026471 · NIDCR · WASHINGTON UNIVERSITY · PI WANG, XIAOWEI · 2017 to 2021
$2.2M
Combined Computational and Experimental Analyses of Gene Regulation by MicroRNAsR35GM141535 · NIGMS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI WANG, XIAOWEI · 2021 to 2025
$2.1M
Multimodal Biomarkers For Oropharyngeal CancerR01CA233873 · NCI · WASHINGTON UNIVERSITY · PI LI, HUA · 2019 to 2024
$2.0M
RADIOMICS-BASED PROGNOSTIC MODEL OF CERVICAL CANCER HABITATSR21CA223799 · NCI · WASHINGTON UNIVERSITY · PI GRIGSBY, PERRY WAYNE, LI, HUA · 2018 to 2019
$368k
NCI NIH HHS R01 CA233873NCI NIH HHS R21 CA223799NIDCR NIH HHS R01 DE026471NIGMS NIH HHS R35 GM141535
6 · The paper itself

Abstract

Predicting early in treatment whether a tumor is likely to be responsive is a difficult yet important task to support clinical decision-making. Studies have shown that multimodal biomarkers could provide complementary information and lead to more accurate treatment outcome prognosis than unimodal biomarkers. However, the prognosis accuracy could be affected by multimodal data heterogeneity and incompleteness. The small-sized and imbalance datasets also bring additional challenges for training a designed prognosis model. In this study, a modular framework employing multimodal biomarkers for cancer treatment outcome prediction was proposed. It includes four modules of synthetic data generation, deep feature extraction, multimodal feature fusion, and classification to address the challenges described above. The feasibility and advantages of the designed framework were demonstrated through an example study, in which the goal was to stratify oropharyngeal squamous cell carcinoma (OPSCC) patients with low- and high-risks of treatment failures by use of positron emission tomography (PET) image data and microRNA (miRNA) biomarkers. The superior prognosis performance and the comparison with other methods demonstrated the efficiency of the proposed framework and its ability of enabling seamless integration, validation and comparison of various algorithms in each module of the framework. The limitation and future work was discussed as well.

Indexed as

cancer therapydeep learningmicroRNA expressionsmodular frameworkMultimodal biomarkersPET imagestreatment outcome prediction

Identifiers

PMID35520102
PMCPMC9066560

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.